MANE
Veradermics, Incorporated
NYSE: MANE · HEALTHCARE · BIOTECHNOLOGY
$99.00
-7.09% today
Updated 2026-04-30
Market cap
$3.74B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.37
Dividend yield
—
52W range
$32 – $110
Volume
0.5M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$95.33
-3.71%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-23.63M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-16.49M | $-26.49M | $-70.00M | $-21.85M |
| EPS | — | — | — | $-2.37 |
| Free cash flow | $-13.51M | $-23.69M | $-71.63M | $-23.63M |
| Profit margin | — | — | — | — |
Peer comparison
Smart narrative
Veradermics, Incorporated trades at $99.00. Our Smart Value Score of 23/100 indicates the stock is weak.
Frequently asked questions
What is Veradermics, Incorporated's stock price?
Veradermics, Incorporated (MANE) trades at $99.00.
Is Veradermics, Incorporated overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell).
What is the price target of Veradermics, Incorporated (MANE)?
The analyst target price is $95.33, representing -3.7% downside from the current price of $99.00.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio—
ROE-72.10%
Beta—
50D MA$59.01
200D MA$56.66
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—